Commission Implementing Regulation (EU) 2017/157 of 30 January 2017 renewing the approval of the active substance thiabendazole in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540/2011 (Text with EEA relevance. )

• CELEX: Implementing Regulation (EU) 2017/157
• Articles: 5

Article 1 Renewal of the approval of active substance

The approval of the active substance thiabendazole, as specified in Annex I, is renewed subject to the conditions laid down in that Annex.

Article 2 Amendments to Implementing Regulation (EU) No 540/2011

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with Annex II to this Regulation.

Article 3 Entry into force and date of application

This Regulation shall enter into force the twentieth day following that of its publication in the Official Journal of the European Union .

It shall apply from 1 April 2017.

Schedules & Appendices

ANNEX I

ANNEX I

Common Name, Identification Numbers

IUPAC Name

Purity  ( 1 )

Date of approval

Expiration of approval

Specific provisions

Thiabendazole

2-(thiazol-4-yl)benzimidazole

≥ 985 g/kg

1 April 2017

31 March 2032

For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on thiabendazole, and in particular Appendices I and II thereof, shall be taken into account.

In this overall assessment Member States shall pay particular attention to:

—

the protection of operators and consumers,

—

the protection of groundwater,

—

the control of waste water from post-harvest uses.

Conditions of use shall include risk mitigation measures, where appropriate.

The applicant shall submit by 31 March 2019 to the Commission, the Member States and the Authority confirmatory information regarding Level 2 tests as currently indicated in the OECD Conceptual Framework investigating the potential for endocrine-mediated effects of thiabendazole.

CAS No 148-79-8

CIPAC No 323

( 1 )   Further details on identity and specification of active substance are provided in the review report.

ANNEX II

ANNEX II

The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in Part A, entry 17 on thiabendazole is deleted;

(2)

in Part B, the following entry is added:

Common Name, Identification Numbers

IUPAC Name

Purity  ( *1 )

Date of approval

Expiration of approval

Specific provisions

‘105

Thiabendazole

2-(thiazol-4-yl)benzimidazole

≥ 985 g/kg

1 April 2017

31 March 2032

For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the review report on thiabendazole, and in particular Appendices I and II thereof, shall be taken into account.

In this overall assessment Member States shall pay particular attention to:

—

the protection of operators and consumers,

—

the protection of groundwater,

—

the control of waste water from post-harvest uses.

Conditions of use shall include risk mitigation measures, where appropriate.

The applicant shall submit by 31 March 2019 to the Commission, the Member States and the Authority confirmatory information regarding Level 2 tests as currently indicated in the OECD Conceptual Framework investigating the potential for endocrine-mediated effects of thiabendazole.’

CAS No 148-79-8

CIPAC No 323

( *1 )   Further details on identity and specification of active substance are provided in the review report.